China HPV Demand Shaping Merck But Competitors Catching Up

Local Nine-Valent Options In Wings

 
• By Brian Yang

Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.

Multi-nationals are set to lose market share in insulin to Chinese competitors in China.
China HPV race shapes Merck, leaves competitors lag behind • Source: Alamy

More from China

More from Focus On Asia